Results 131 to 140 of about 34,651 (222)

Association Discovery Approach in Healthcare Big Data to Identify Drug Safety and Drug Repurposing Signals

Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 228-240, January 2026.
Data science approaches have been increasingly implemented in healthcare big data to evaluate the safety and effectiveness of drugs. Association discovery is a data mining approach that finds potentially associated elements in high‐dimensional data. We present a novel implementation of the association discovery approach in longitudinal healthcare data ...
George S. Q. Tan, Lynn Miller, Sam Wade, Jenni Ilomäki, Dickson Lukose, Jia Rong, Geoffrey I. Webb   +6 more
wiley   +1 more source

Hepatobiliary Adverse Events Associated with Pembrolizumab: A Pharmacovigilance Study from the FDA Adverse Event Reporting System (FAERS) Database

Pharmacoepidemiology
Background: Immuno-oncology has transformed cancer treatment, with immune checkpoint inhibitors (ICIs) like pembrolizumab playing a key role. While highly effective, these therapies can also cause immune-related adverse events.
Connor Frey
doaj   +1 more source

Anxiolytic Medication Use in Low‐ Middle‐ and High‐Income Countries: A World Mental Health Surveys Report

Human Psychopharmacology: Clinical and Experimental, Volume 41, Issue 1, January 2026.
ABSTRACT Background Anxiolytic medications, particularly benzodiazepines, are widely prescribed, giving impetus to long‐standing debates about how often these agents should be employed in clinical practice. There are, however, few cross‐country studies of the pharmacoepidemiology of these agents. We report on the frequency of anxiolytic medication use,
Dan J. Stein, Alan E. Kazdin, David S. Baldwin, Meredith G. Harris, Irving Hwang, Julia R. Pozuelo, Nancy A. Sampson, Peter Woodruff, Maria Carmen Viana, Sergio Aguilar‐Gaxiola, Ali Al‐Hamzawi, Jordi Alonso, Laura Helena Andrade, Corina Benjet, Ronny Bruffaerts, José‐Miguel Caldas‐de‐Almeida, Stephanie Chardoul, Giovanni de Girolamo, Oye Gureje, Josep M. Haro, Elie G. Karam, Aimee Karam, Viviane Kovess‐Masfety, Fernando Navarro‐Mateu, Daisuke Nishi, José Posada‐Villa, Annelieke Roest, Juan Carlos Stagnaro, Cristian Vladescu, Daniel V. Vigo, Ronald C. Kessler, the WHO World Mental Health Survey collaborators   +31 more
wiley   +1 more source

Pharmacoepidemiology [PDF]

Journal of the Korean Medical Association, 2001
openaire   +2 more sources

Antibiotic Consumption Patterns in Urban Coari, Amazonas: High Azithromycin Use and COVID-19-Related Prescriptions

Pharmacoepidemiology
Background/Objectivses: Antibiotic consumption patterns in remote urban areas of the Amazon region are poorly understood. This study aimed to analyze antibiotic use in the adult population of Coari, a municipality in Amazonas, Brazil.
Rodrigo Silva Marcelino, Edivã Bernardo da Silva, Abel Santiago Muri Gama, Ananias Facundes Guimarães, Silvia Regina Secoli, Albert Figueras   +5 more
doaj   +1 more source

Association Between Depression and Polypharmacy in Older Adults—A Systematic Review and Meta‐Analysis

Journal of General and Family Medicine, Volume 27, Issue 1, January 2026.
ABSTRACT Background Depression and polypharmacy are both common among older adults and may be closely interrelated. Methods This systematic review and meta‐analysis examined the association between depression and polypharmacy by searching EMBASE, PubMed, Web of Science, and PsycINFO from inception to 18 May 2023.
Yi‐Hsin Wang, Tsung‐Yu Tsai, Hung‐Chang Chou, Huei Chung   +3 more
wiley   +1 more source

A Systematic Review of Potential Opioid Prescribing Safety Indicators

Pharmacoepidemiology
Background/Objectives: This systematic review aimed to identify a comprehensive list of potential opioid-related indicators from the published literature to assess prescribing safety in any setting.
Wael Y. Khawagi, Neetu Bansal, Nan Shang, Li-Chia Chen   +3 more
doaj   +1 more source

Female Patients With Mucopolysaccharidosis II (MPS II): Insights From the Hunter Outcome Survey

JIMD Reports, Volume 67, Issue 1, January 2026.
ABSTRACT Mucopolysaccharidosis II is a rare, X‐linked disease, with very few reports of affected female patients. Natural history data describe a predominantly male population, and appropriate disease characterization in female patients is lacking. This analysis explores the somatic disease burden and clinical progression of female patients with MPS II
Barbara K. Burton, Hernan Amartino, Roberto Giugliani, Christoph Kampmann, Julian Raiman, Maurizio Scarpa, Anna Tylki‐Szymańska, Jennifer Audi, Jaco Botha, Siddarth Jain, Joseph Muenzer   +10 more
wiley   +1 more source

Concordance of Lung Cancer, Melanoma, and Renal Cell Cancer Diagnosis Information Recorded in Health Care Databases in England: Analysis of Linkage Between Primary Care, Hospital Care, and Cancer Registry Data

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 1, January 2026.
ABSTRACT Purpose Real‐world evidence (RWE) addresses clinical trial limitations by capturing more representative patient populations and improves evaluation of anticancer treatments, although it becomes available only years after market authorization.
Paul D. Kruithof, Patrick C. Souverein, Johanna H. M. Driessen, Lizza E. L. Hendriks, Sander Croes, Robin M. J. M. van Geel   +5 more
wiley   +1 more source

Stigma, Scarcity and the Price of Legitimacy: Chronic Pain Advocacy and the Politics of Pharmaceutical Partnerships in Canada

Sociology of Health &Illness, Volume 48, Issue 1, January 2026.
ABSTRACT This study examines how chronic pain advocates in Canada navigated fraught relationships with pharmaceutical companies amid escalating concerns about the adverse public health impacts of opioids. Drawing on 22 qualitative interviews with professional chronic pain advocates, it examines how advocates navigated their complex relationships with ...
Daniel Eisenkraft Klein, Benjamin Hawkins, Quinn Grundy, Robert Schwartz   +3 more
wiley   +1 more source